The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XIX.o

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

Publications

Parambil JG, Myers JL, Aubry MC, Ryu JH

Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy.

Chest 2007 Jul;132;50-7 — 2007 Jul — 50-7

Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.

Investigational new drugs 2007 Jun;25;279-81 — 2007 Jun — 279-81

Nagashima O, Tajima K, Ito J, Kajiyama Y, Shimanuki Y, Miura K, Sato K, Miyamoto H, Uekusa T, Suzuki T, Takahashi K, Fukuchi Y

[A case of non-small cell lung cancer accompanied with hemorrhage after chemotherapy including gemcitabine].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 2006 Mar;44;215-9 — 2006 Mar — 215-9

Maniwa K, Tanaka E, Inoue T, Kato T, Sakuramoto M, Minakuchi M, Maeda Y, Noma S, Kobashi Y, Taguchi Y

An autopsy case of acute pulmonary toxicity associated with gemcitabine.

Internal medicine (Tokyo, Japan) 2003 Oct;42;1022-5 — 2003 Oct — 1022-5

Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL

Diffuse alveolar damage in a patient treated with gemcitabine.

The European respiratory journal 1998 Feb;11;504-6 — 1998 Feb — 504-6